Programed cell death protein 1 (PD-1) is a cell surface receptor. PD-1 and its ligand PD-L1 are crucial immune checkpoints to downregulate T cell activation, tolerance and immunopathology. Several types of cancer cells overexpress PD-L1 in order to escape from the PD-1/PD-L1 immunosurveillance mechanism.
Human PD-L1 inhibitor III is a peptide-based molecule. It binds to human PD-1 and inhibits PD-1/PD-L1 binding. This peptide, hPDL-1 inhibitor III has anchor residues (underlined), TEKDYRHGNIRMKLAYDL that influence binding of hPD-L1 to hPD-1. Developing inhibitors specifically blocking the PD-1/PD-L1 pathway has become a popular approach toward cancer treatment.
Peptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.W/Mr. | 2223.7 |
Sequence | One Letter Code: TEKDYRHGNIRMKLAYDL Three Letter Code: H-Thr-Glu-Lys-Asp-Tyr-Arg-His-Gly-Asn-Ile-Arg-Met-Lys-Leu-Ala-Tyr-Asp-Leu-OH |
References | 1. Bardhan K., et.al, Front Immunol 7(550), (2016); 2. Li Q., et.al, Oncotarget 7(40), 64967-64976 (2016); 3. D'Errico G., et.al, Clin Transl Med 6(1), 3-12 (2017) |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.